

# Global Mitogen-Activated Protein Kinase Inhibitors Supply, Demand and Key Producers, 2023-2029

<https://marketpublishers.com/r/G6AF55ED9A7AEN.html>

Date: February 2023

Pages: 105

Price: US\$ 4,480.00 (Single User License)

ID: G6AF55ED9A7AEN

## Abstracts

The global Mitogen-Activated Protein Kinase Inhibitors market size is expected to reach \$ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

The mitogen-activated protein kinase (MAPK) family is a class of serine/threonine protein kinases that can transduce extracellular signals to the cell and nucleus through a conserved three-level cascade reaction (MAPKKK -MAPKK-MAPK) activates transcription factors that regulate gene expression. This pathway exists in most cells and is related to a variety of cell functions, and can participate in various physiological processes such as cell movement, apoptosis, differentiation, growth and proliferation.

This report studies the global Mitogen-Activated Protein Kinase Inhibitors demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Mitogen-Activated Protein Kinase Inhibitors, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Mitogen-Activated Protein Kinase Inhibitors that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Mitogen-Activated Protein Kinase Inhibitors total market, 2018-2029, (USD Million)

Global Mitogen-Activated Protein Kinase Inhibitors total market by region & country, CAGR, 2018-2029, (USD Million)

U.S. VS China: Mitogen-Activated Protein Kinase Inhibitors total market, key domestic companies and share, (USD Million)

Global Mitogen-Activated Protein Kinase Inhibitors revenue by player and market share 2018-2023, (USD Million)

Global Mitogen-Activated Protein Kinase Inhibitors total market by Type, CAGR, 2018-2029, (USD Million)

Global Mitogen-Activated Protein Kinase Inhibitors total market by Application, CAGR, 2018-2029, (USD Million)

This reports profiles major players in the global Mitogen-Activated Protein Kinase Inhibitors market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GEn1E Lifesciences Inc, F. Hoffmann-La Roche Ltd, Lilly, AstraZeneca, Merck & Co., Inc, HepaRegeniX GmbH, GSK plc, Mereo Biopharma Group PLC and Kura Oncology, Inc, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Mitogen-Activated Protein Kinase Inhibitors market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Mitogen-Activated Protein Kinase Inhibitors Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

#### Global Mitogen-Activated Protein Kinase Inhibitors Market, Segmentation by Type

Extracellular Signal-Regulated Kinase Signaling Pathway

C-Jun N-Terminal Kinase/Stress-Activated Protein Signaling Pathway

P38 MAPK Signaling Pathway

ERK5/Macromitogen-Activated Protein Kinase Signaling Pathway

#### Global Mitogen-Activated Protein Kinase Inhibitors Market, Segmentation by Application

Colon Cancer

Acute Myelogenous Leukemia

Malignant Melanoma

Pancreatic Cancer

Breast Cancer

Other

## Companies Profiled:

GEn1E Lifesciences Inc

F. Hoffmann-La Roche Ltd

Lilly

AstraZeneca

Merck & Co., Inc

HepaRegeniX GmbH

GSK plc

Mereo Biopharma Group PLC

Kura Oncology, Inc

eFFECTOR Therapeutics, Inc

Selleck

## Key Questions Answered

1. How big is the global Mitogen-Activated Protein Kinase Inhibitors market?
2. What is the demand of the global Mitogen-Activated Protein Kinase Inhibitors market?
3. What is the year over year growth of the global Mitogen-Activated Protein Kinase Inhibitors market?
4. What is the total value of the global Mitogen-Activated Protein Kinase Inhibitors market?

5. Who are the major players in the global Mitogen-Activated Protein Kinase Inhibitors market?

6. What are the growth factors driving the market demand?

## Contents

### 1 SUPPLY SUMMARY

- 1.1 Mitogen-Activated Protein Kinase Inhibitors Introduction
- 1.2 World Mitogen-Activated Protein Kinase Inhibitors Market Size & Forecast (2018 & 2022 & 2029)
- 1.3 World Mitogen-Activated Protein Kinase Inhibitors Total Market by Region (by Headquarter Location)
  - 1.3.1 World Mitogen-Activated Protein Kinase Inhibitors Market Size by Region (2018-2029), (by Headquarter Location)
  - 1.3.2 United States Mitogen-Activated Protein Kinase Inhibitors Market Size (2018-2029)
  - 1.3.3 China Mitogen-Activated Protein Kinase Inhibitors Market Size (2018-2029)
  - 1.3.4 Europe Mitogen-Activated Protein Kinase Inhibitors Market Size (2018-2029)
  - 1.3.5 Japan Mitogen-Activated Protein Kinase Inhibitors Market Size (2018-2029)
  - 1.3.6 South Korea Mitogen-Activated Protein Kinase Inhibitors Market Size (2018-2029)
  - 1.3.7 ASEAN Mitogen-Activated Protein Kinase Inhibitors Market Size (2018-2029)
  - 1.3.8 India Mitogen-Activated Protein Kinase Inhibitors Market Size (2018-2029)
- 1.4 Market Drivers, Restraints and Trends
  - 1.4.1 Mitogen-Activated Protein Kinase Inhibitors Market Drivers
  - 1.4.2 Factors Affecting Demand
  - 1.4.3 Mitogen-Activated Protein Kinase Inhibitors Major Market Trends
- 1.5 Influence of COVID-19 and Russia-Ukraine War
  - 1.5.1 Influence of COVID-19
  - 1.5.2 Influence of Russia-Ukraine War

### 2 DEMAND SUMMARY

- 2.1 World Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029)
- 2.2 World Mitogen-Activated Protein Kinase Inhibitors Consumption Value by Region
  - 2.2.1 World Mitogen-Activated Protein Kinase Inhibitors Consumption Value by Region (2018-2023)
  - 2.2.2 World Mitogen-Activated Protein Kinase Inhibitors Consumption Value Forecast by Region (2024-2029)
- 2.3 United States Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029)
- 2.4 China Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029)

2.5 Europe Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029)

2.6 Japan Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029)

2.7 South Korea Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029)

2.8 ASEAN Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029)

2.9 India Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029)

### **3 WORLD MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS COMPANIES COMPETITIVE ANALYSIS**

3.1 World Mitogen-Activated Protein Kinase Inhibitors Revenue by Player (2018-2023)

3.2 Industry Rank and Concentration Rate (CR)

3.2.1 Global Mitogen-Activated Protein Kinase Inhibitors Industry Rank of Major Players

3.2.2 Global Concentration Ratios (CR4) for Mitogen-Activated Protein Kinase Inhibitors in 2022

3.2.3 Global Concentration Ratios (CR8) for Mitogen-Activated Protein Kinase Inhibitors in 2022

3.3 Mitogen-Activated Protein Kinase Inhibitors Company Evaluation Quadrant

3.4 Mitogen-Activated Protein Kinase Inhibitors Market: Overall Company Footprint Analysis

3.4.1 Mitogen-Activated Protein Kinase Inhibitors Market: Region Footprint

3.4.2 Mitogen-Activated Protein Kinase Inhibitors Market: Company Product Type Footprint

3.4.3 Mitogen-Activated Protein Kinase Inhibitors Market: Company Product Application Footprint

3.5 Competitive Environment

3.5.1 Historical Structure of the Industry

3.5.2 Barriers of Market Entry

3.5.3 Factors of Competition

3.6 Mergers, Acquisitions Activity

### **4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)**

4.1 United States VS China: Mitogen-Activated Protein Kinase Inhibitors Revenue Comparison (by Headquarter Location)

4.1.1 United States VS China: Mitogen-Activated Protein Kinase Inhibitors Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)

4.1.2 United States VS China: Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share Comparison (2018 & 2022 & 2029)

4.2 United States Based Companies VS China Based Companies: Mitogen-Activated Protein Kinase Inhibitors Consumption Value Comparison

4.2.1 United States VS China: Mitogen-Activated Protein Kinase Inhibitors Consumption Value Comparison (2018 & 2022 & 2029)

4.2.2 United States VS China: Mitogen-Activated Protein Kinase Inhibitors Consumption Value Market Share Comparison (2018 & 2022 & 2029)

4.3 United States Based Mitogen-Activated Protein Kinase Inhibitors Companies and Market Share, 2018-2023

4.3.1 United States Based Mitogen-Activated Protein Kinase Inhibitors Companies, Headquarters (States, Country)

4.3.2 United States Based Companies Mitogen-Activated Protein Kinase Inhibitors Revenue, (2018-2023)

4.4 China Based Companies Mitogen-Activated Protein Kinase Inhibitors Revenue and Market Share, 2018-2023

4.4.1 China Based Mitogen-Activated Protein Kinase Inhibitors Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies Mitogen-Activated Protein Kinase Inhibitors Revenue, (2018-2023)

4.5 Rest of World Based Mitogen-Activated Protein Kinase Inhibitors Companies and Market Share, 2018-2023

4.5.1 Rest of World Based Mitogen-Activated Protein Kinase Inhibitors Companies, Headquarters (States, Country)

4.5.2 Rest of World Based Companies Mitogen-Activated Protein Kinase Inhibitors Revenue, (2018-2023)

## **5 MARKET ANALYSIS BY TYPE**

5.1 World Mitogen-Activated Protein Kinase Inhibitors Market Size Overview by Type: 2018 VS 2022 VS 2029

5.2 Segment Introduction by Type

5.2.1 Extracellular Signal-Regulated Kinase Signaling Pathway

5.2.2 C-Jun N-Terminal Kinase/Stress-Activated Protein Signaling Pathway

5.2.3 P38 MAPK Signaling Pathway

5.2.4 ERK5/Macromitogen-Activated Protein Kinase Signaling Pathway

5.3 Market Segment by Type

5.3.1 World Mitogen-Activated Protein Kinase Inhibitors Market Size by Type (2018-2023)

5.3.2 World Mitogen-Activated Protein Kinase Inhibitors Market Size by Type (2024-2029)

5.3.3 World Mitogen-Activated Protein Kinase Inhibitors Market Size Market Share by Type (2018-2029)

## **6 MARKET ANALYSIS BY APPLICATION**

6.1 World Mitogen-Activated Protein Kinase Inhibitors Market Size Overview by Application: 2018 VS 2022 VS 2029

6.2 Segment Introduction by Application

6.2.1 Colon Cancer

6.2.2 Acute Myelogenous Leukemia

6.2.3 Malignant Melanoma

6.2.4 Pancreatic Cancer

6.2.5 Pancreatic Cancer

6.2.6 Other

6.3 Market Segment by Application

6.3.1 World Mitogen-Activated Protein Kinase Inhibitors Market Size by Application (2018-2023)

6.3.2 World Mitogen-Activated Protein Kinase Inhibitors Market Size by Application (2024-2029)

6.3.3 World Mitogen-Activated Protein Kinase Inhibitors Market Size by Application (2018-2029)

## **7 COMPANY PROFILES**

7.1 GEn1E Lifesciences Inc

7.1.1 GEn1E Lifesciences Inc Details

7.1.2 GEn1E Lifesciences Inc Major Business

7.1.3 GEn1E Lifesciences Inc Mitogen-Activated Protein Kinase Inhibitors Product and Services

7.1.4 GEn1E Lifesciences Inc Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023)

7.1.5 GEn1E Lifesciences Inc Recent Developments/Updates

7.1.6 GEn1E Lifesciences Inc Competitive Strengths & Weaknesses

7.2 F. Hoffmann-La Roche Ltd

7.2.1 F. Hoffmann-La Roche Ltd Details

7.2.2 F. Hoffmann-La Roche Ltd Major Business

7.2.3 F. Hoffmann-La Roche Ltd Mitogen-Activated Protein Kinase Inhibitors Product and Services

7.2.4 F. Hoffmann-La Roche Ltd Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023)

7.2.5 F. Hoffmann-La Roche Ltd Recent Developments/Updates

7.2.6 F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses

7.3 Lilly

7.3.1 Lilly Details

7.3.2 Lilly Major Business

7.3.3 Lilly Mitogen-Activated Protein Kinase Inhibitors Product and Services

7.3.4 Lilly Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023)

7.3.5 Lilly Recent Developments/Updates

7.3.6 Lilly Competitive Strengths & Weaknesses

7.4 AstraZeneca

7.4.1 AstraZeneca Details

7.4.2 AstraZeneca Major Business

7.4.3 AstraZeneca Mitogen-Activated Protein Kinase Inhibitors Product and Services

7.4.4 AstraZeneca Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023)

7.4.5 AstraZeneca Recent Developments/Updates

7.4.6 AstraZeneca Competitive Strengths & Weaknesses

7.5 Merck & Co., Inc

7.5.1 Merck & Co., Inc Details

7.5.2 Merck & Co., Inc Major Business

7.5.3 Merck & Co., Inc Mitogen-Activated Protein Kinase Inhibitors Product and Services

7.5.4 Merck & Co., Inc Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023)

7.5.5 Merck & Co., Inc Recent Developments/Updates

7.5.6 Merck & Co., Inc Competitive Strengths & Weaknesses

7.6 HepaRegeniX GmbH

7.6.1 HepaRegeniX GmbH Details

7.6.2 HepaRegeniX GmbH Major Business

7.6.3 HepaRegeniX GmbH Mitogen-Activated Protein Kinase Inhibitors Product and Services

7.6.4 HepaRegeniX GmbH Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023)

- 7.6.5 HepaRegeniX GmbH Recent Developments/Updates
- 7.6.6 HepaRegeniX GmbH Competitive Strengths & Weaknesses
- 7.7 GSK plc
  - 7.7.1 GSK plc Details
  - 7.7.2 GSK plc Major Business
  - 7.7.3 GSK plc Mitogen-Activated Protein Kinase Inhibitors Product and Services
  - 7.7.4 GSK plc Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.7.5 GSK plc Recent Developments/Updates
  - 7.7.6 GSK plc Competitive Strengths & Weaknesses
- 7.8 Mereo Biopharma Group PLC
  - 7.8.1 Mereo Biopharma Group PLC Details
  - 7.8.2 Mereo Biopharma Group PLC Major Business
  - 7.8.3 Mereo Biopharma Group PLC Mitogen-Activated Protein Kinase Inhibitors Product and Services
  - 7.8.4 Mereo Biopharma Group PLC Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.8.5 Mereo Biopharma Group PLC Recent Developments/Updates
  - 7.8.6 Mereo Biopharma Group PLC Competitive Strengths & Weaknesses
- 7.9 Kura Oncology, Inc
  - 7.9.1 Kura Oncology, Inc Details
  - 7.9.2 Kura Oncology, Inc Major Business
  - 7.9.3 Kura Oncology, Inc Mitogen-Activated Protein Kinase Inhibitors Product and Services
  - 7.9.4 Kura Oncology, Inc Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.9.5 Kura Oncology, Inc Recent Developments/Updates
  - 7.9.6 Kura Oncology, Inc Competitive Strengths & Weaknesses
- 7.10 eFFECTOR Therapeutics, Inc
  - 7.10.1 eFFECTOR Therapeutics, Inc Details
  - 7.10.2 eFFECTOR Therapeutics, Inc Major Business
  - 7.10.3 eFFECTOR Therapeutics, Inc Mitogen-Activated Protein Kinase Inhibitors Product and Services
  - 7.10.4 eFFECTOR Therapeutics, Inc Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
  - 7.10.5 eFFECTOR Therapeutics, Inc Recent Developments/Updates
  - 7.10.6 eFFECTOR Therapeutics, Inc Competitive Strengths & Weaknesses
- 7.11 Selleck
  - 7.11.1 Selleck Details

- 7.11.2 Selleck Major Business
- 7.11.3 Selleck Mitogen-Activated Protein Kinase Inhibitors Product and Services
- 7.11.4 Selleck Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023)
- 7.11.5 Selleck Recent Developments/Updates
- 7.11.6 Selleck Competitive Strengths & Weaknesses

## **8 INDUSTRY CHAIN ANALYSIS**

- 8.1 Mitogen-Activated Protein Kinase Inhibitors Industry Chain
- 8.2 Mitogen-Activated Protein Kinase Inhibitors Upstream Analysis
- 8.3 Mitogen-Activated Protein Kinase Inhibitors Midstream Analysis
- 8.4 Mitogen-Activated Protein Kinase Inhibitors Downstream Analysis

## **9 RESEARCH FINDINGS AND CONCLUSION**

## **10 APPENDIX**

- 10.1 Methodology
- 10.2 Research Process and Data Source
- 10.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. World Mitogen-Activated Protein Kinase Inhibitors Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)

Table 2. World Mitogen-Activated Protein Kinase Inhibitors Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)

Table 3. World Mitogen-Activated Protein Kinase Inhibitors Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)

Table 4. World Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share by Region (2018-2023), (by Headquarter Location)

Table 5. World Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share by Region (2024-2029), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World Mitogen-Activated Protein Kinase Inhibitors Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)

Table 8. World Mitogen-Activated Protein Kinase Inhibitors Consumption Value by Region (2018-2023) & (USD Million)

Table 9. World Mitogen-Activated Protein Kinase Inhibitors Consumption Value Forecast by Region (2024-2029) & (USD Million)

Table 10. World Mitogen-Activated Protein Kinase Inhibitors Revenue by Player (2018-2023) & (USD Million)

Table 11. Revenue Market Share of Key Mitogen-Activated Protein Kinase Inhibitors Players in 2022

Table 12. World Mitogen-Activated Protein Kinase Inhibitors Industry Rank of Major Player, Based on Revenue in 2022

Table 13. Global Mitogen-Activated Protein Kinase Inhibitors Company Evaluation Quadrant

Table 14. Head Office of Key Mitogen-Activated Protein Kinase Inhibitors Player

Table 15. Mitogen-Activated Protein Kinase Inhibitors Market: Company Product Type Footprint

Table 16. Mitogen-Activated Protein Kinase Inhibitors Market: Company Product Application Footprint

Table 17. Mitogen-Activated Protein Kinase Inhibitors Mergers & Acquisitions Activity

Table 18. United States VS China Mitogen-Activated Protein Kinase Inhibitors Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)

Table 19. United States VS China Mitogen-Activated Protein Kinase Inhibitors Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)

|                                                                                                                                                 |
|-------------------------------------------------------------------------------------------------------------------------------------------------|
| Table 20. United States Based Mitogen-Activated Protein Kinase Inhibitors Companies, Headquarters (States, Country)                             |
| Table 21. United States Based Companies Mitogen-Activated Protein Kinase Inhibitors Revenue, (2018-2023) & (USD Million)                        |
| Table 22. United States Based Companies Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share (2018-2023)                            |
| Table 23. China Based Mitogen-Activated Protein Kinase Inhibitors Companies, Headquarters (Province, Country)                                   |
| Table 24. China Based Companies Mitogen-Activated Protein Kinase Inhibitors Revenue, (2018-2023) & (USD Million)                                |
| Table 25. China Based Companies Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share (2018-2023)                                    |
| Table 26. Rest of World Based Mitogen-Activated Protein Kinase Inhibitors Companies, Headquarters (States, Country)                             |
| Table 27. Rest of World Based Companies Mitogen-Activated Protein Kinase Inhibitors Revenue, (2018-2023) & (USD Million)                        |
| Table 28. Rest of World Based Companies Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share (2018-2023)                            |
| Table 29. World Mitogen-Activated Protein Kinase Inhibitors Market Size by Type, (USD Million), 2018 & 2022 & 2029                              |
| Table 30. World Mitogen-Activated Protein Kinase Inhibitors Market Size by Type (2018-2023) & (USD Million)                                     |
| Table 31. World Mitogen-Activated Protein Kinase Inhibitors Market Size by Type (2024-2029) & (USD Million)                                     |
| Table 32. World Mitogen-Activated Protein Kinase Inhibitors Market Size by Application, (USD Million), 2018 & 2022 & 2029                       |
| Table 33. World Mitogen-Activated Protein Kinase Inhibitors Market Size by Application (2018-2023) & (USD Million)                              |
| Table 34. World Mitogen-Activated Protein Kinase Inhibitors Market Size by Application (2024-2029) & (USD Million)                              |
| Table 35. GEn1E Lifesciences Inc Basic Information, Area Served and Competitors                                                                 |
| Table 36. GEn1E Lifesciences Inc Major Business                                                                                                 |
| Table 37. GEn1E Lifesciences Inc Mitogen-Activated Protein Kinase Inhibitors Product and Services                                               |
| Table 38. GEn1E Lifesciences Inc Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million) |
| Table 39. GEn1E Lifesciences Inc Recent Developments/Updates                                                                                    |
| Table 40. GEn1E Lifesciences Inc Competitive Strengths & Weaknesses                                                                             |
| Table 41. F. Hoffmann-La Roche Ltd Basic Information, Area Served and Competitors                                                               |

|                                                                                                                                                   |
|---------------------------------------------------------------------------------------------------------------------------------------------------|
| Table 42. F. Hoffmann-La Roche Ltd Major Business                                                                                                 |
| Table 43. F. Hoffmann-La Roche Ltd Mitogen-Activated Protein Kinase Inhibitors Product and Services                                               |
| Table 44. F. Hoffmann-La Roche Ltd Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million) |
| Table 45. F. Hoffmann-La Roche Ltd Recent Developments/Updates                                                                                    |
| Table 46. F. Hoffmann-La Roche Ltd Competitive Strengths & Weaknesses                                                                             |
| Table 47. Lilly Basic Information, Area Served and Competitors                                                                                    |
| Table 48. Lilly Major Business                                                                                                                    |
| Table 49. Lilly Mitogen-Activated Protein Kinase Inhibitors Product and Services                                                                  |
| Table 50. Lilly Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)                    |
| Table 51. Lilly Recent Developments/Updates                                                                                                       |
| Table 52. Lilly Competitive Strengths & Weaknesses                                                                                                |
| Table 53. AstraZeneca Basic Information, Area Served and Competitors                                                                              |
| Table 54. AstraZeneca Major Business                                                                                                              |
| Table 55. AstraZeneca Mitogen-Activated Protein Kinase Inhibitors Product and Services                                                            |
| Table 56. AstraZeneca Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)              |
| Table 57. AstraZeneca Recent Developments/Updates                                                                                                 |
| Table 58. AstraZeneca Competitive Strengths & Weaknesses                                                                                          |
| Table 59. Merck & Co., Inc Basic Information, Area Served and Competitors                                                                         |
| Table 60. Merck & Co., Inc Major Business                                                                                                         |
| Table 61. Merck & Co., Inc Mitogen-Activated Protein Kinase Inhibitors Product and Services                                                       |
| Table 62. Merck & Co., Inc Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)         |
| Table 63. Merck & Co., Inc Recent Developments/Updates                                                                                            |
| Table 64. Merck & Co., Inc Competitive Strengths & Weaknesses                                                                                     |
| Table 65. HepaRegeniX GmbH Basic Information, Area Served and Competitors                                                                         |
| Table 66. HepaRegeniX GmbH Major Business                                                                                                         |
| Table 67. HepaRegeniX GmbH Mitogen-Activated Protein Kinase Inhibitors Product and Services                                                       |
| Table 68. HepaRegeniX GmbH Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)         |
| Table 69. HepaRegeniX GmbH Recent Developments/Updates                                                                                            |
| Table 70. HepaRegeniX GmbH Competitive Strengths & Weaknesses                                                                                     |
| Table 71. GSK plc Basic Information, Area Served and Competitors                                                                                  |

Table 72. GSK plc Major Business

Table 73. GSK plc Mitogen-Activated Protein Kinase Inhibitors Product and Services

Table 74. GSK plc Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 75. GSK plc Recent Developments/Updates

Table 76. GSK plc Competitive Strengths & Weaknesses

Table 77. Mereo Biopharma Group PLC Basic Information, Area Served and Competitors

Table 78. Mereo Biopharma Group PLC Major Business

Table 79. Mereo Biopharma Group PLC Mitogen-Activated Protein Kinase Inhibitors Product and Services

Table 80. Mereo Biopharma Group PLC Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 81. Mereo Biopharma Group PLC Recent Developments/Updates

Table 82. Mereo Biopharma Group PLC Competitive Strengths & Weaknesses

Table 83. Kura Oncology, Inc Basic Information, Area Served and Competitors

Table 84. Kura Oncology, Inc Major Business

Table 85. Kura Oncology, Inc Mitogen-Activated Protein Kinase Inhibitors Product and Services

Table 86. Kura Oncology, Inc Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 87. Kura Oncology, Inc Recent Developments/Updates

Table 88. Kura Oncology, Inc Competitive Strengths & Weaknesses

Table 89. eFFECTOR Therapeutics, Inc Basic Information, Area Served and Competitors

Table 90. eFFECTOR Therapeutics, Inc Major Business

Table 91. eFFECTOR Therapeutics, Inc Mitogen-Activated Protein Kinase Inhibitors Product and Services

Table 92. eFFECTOR Therapeutics, Inc Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 93. eFFECTOR Therapeutics, Inc Recent Developments/Updates

Table 94. Selleck Basic Information, Area Served and Competitors

Table 95. Selleck Major Business

Table 96. Selleck Mitogen-Activated Protein Kinase Inhibitors Product and Services

Table 97. Selleck Mitogen-Activated Protein Kinase Inhibitors Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)

Table 98. Global Key Players of Mitogen-Activated Protein Kinase Inhibitors Upstream (Raw Materials)

Table 99. Mitogen-Activated Protein Kinase Inhibitors Typical Customers



## List Of Figures

### LIST OF FIGURES

Figure 1. Mitogen-Activated Protein Kinase Inhibitors Picture

Figure 2. World Mitogen-Activated Protein Kinase Inhibitors Total Market Size: 2018 & 2022 & 2029, (USD Million)

Figure 3. World Mitogen-Activated Protein Kinase Inhibitors Total Market Size (2018-2029) & (USD Million)

Figure 4. World Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)

Figure 5. World Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share by Region (2018-2029), (by Headquarter Location)

Figure 6. United States Based Company Mitogen-Activated Protein Kinase Inhibitors Revenue (2018-2029) & (USD Million)

Figure 7. China Based Company Mitogen-Activated Protein Kinase Inhibitors Revenue (2018-2029) & (USD Million)

Figure 8. Europe Based Company Mitogen-Activated Protein Kinase Inhibitors Revenue (2018-2029) & (USD Million)

Figure 9. Japan Based Company Mitogen-Activated Protein Kinase Inhibitors Revenue (2018-2029) & (USD Million)

Figure 10. South Korea Based Company Mitogen-Activated Protein Kinase Inhibitors Revenue (2018-2029) & (USD Million)

Figure 11. ASEAN Based Company Mitogen-Activated Protein Kinase Inhibitors Revenue (2018-2029) & (USD Million)

Figure 12. India Based Company Mitogen-Activated Protein Kinase Inhibitors Revenue (2018-2029) & (USD Million)

Figure 13. Mitogen-Activated Protein Kinase Inhibitors Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 16. World Mitogen-Activated Protein Kinase Inhibitors Consumption Value Market Share by Region (2018-2029)

Figure 17. United States Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 18. China Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 19. Europe Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 20. Japan Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 21. South Korea Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 22. ASEAN Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 23. India Mitogen-Activated Protein Kinase Inhibitors Consumption Value (2018-2029) & (USD Million)

Figure 24. Producer Shipments of Mitogen-Activated Protein Kinase Inhibitors by Player Revenue (\$MM) and Market Share (%): 2022

Figure 25. Global Four-firm Concentration Ratios (CR4) for Mitogen-Activated Protein Kinase Inhibitors Markets in 2022

Figure 26. Global Four-firm Concentration Ratios (CR8) for Mitogen-Activated Protein Kinase Inhibitors Markets in 2022

Figure 27. United States VS China: Mitogen-Activated Protein Kinase Inhibitors Revenue Market Share Comparison (2018 & 2022 & 2029)

Figure 28. United States VS China: Mitogen-Activated Protein Kinase Inhibitors Consumption Value Market Share Comparison (2018 & 2022 & 2029)

Figure 29. World Mitogen-Activated Protein Kinase Inhibitors Market Size by Type, (USD Million), 2018 & 2022 & 2029

Figure 30. World Mitogen-Activated Protein Kinase Inhibitors Market Size Market Share by Type in 2022

Figure 31. Extracellular Signal-Regulated Kinase Signaling Pathway

Figure 32. C-Jun N-Terminal Kinase/Stress-Activated Protein Signaling Pathway

Figure 33. P38 MAPK Signaling Pathway

Figure 34. ERK5/Macromitogen-Activated Protein Kinase Signaling Pathway

Figure 35. World Mitogen-Activated Protein Kinase Inhibitors Market Size Market Share by Type (2018-2029)

Figure 36. World Mitogen-Activated Protein Kinase Inhibitors Market Size by Application, (USD Million), 2018 & 2022 & 2029

Figure 37. World Mitogen-Activated Protein Kinase Inhibitors Market Size Market Share by Application in 2022

Figure 38. Colon Cancer

Figure 39. Acute Myelogenous Leukemia

Figure 40. Malignant Melanoma

Figure 41. Pancreatic Cancer

Figure 42. Breast Cancer

Figure 43. Other

Figure 44. Mitogen-Activated Protein Kinase Inhibitors Industrial Chain

Figure 45. Methodology

Figure 46. Research Process and Data Source

## I would like to order

Product name: Global Mitogen-Activated Protein Kinase Inhibitors Supply, Demand and Key Producers, 2023-2029

Product link: <https://marketpublishers.com/r/G6AF55ED9A7AEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6AF55ED9A7AEN.html>